Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Thyroid Cancer Specialty Channel

FDA Approval
FDA Approves Selpercatinib for Adult and Pediatric Patients With Advanced or Metastatic Medullary Thyroid Cancer
09/27/2024
Based on results from the phase 3 LIBRETTO-531 study, the FDA has granted traditional approval to selpercatinib for adult and pediatric patients 2 years and older with advanced or metastatic medullary thyroid cancer harboring a RET mutation.
Based on results from the phase 3 LIBRETTO-531 study, the FDA has granted traditional approval to selpercatinib for adult and pediatric patients 2 years and older with advanced or metastatic medullary thyroid cancer harboring a RET mutation.
Based on results from the phase...
09/27/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
FDA Approval
FDA Approves Selpercatinib for Adult and Pediatric Patients With RET Fusion-Positive Thyroid Cancer
06/13/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the LIBRETTO-001 and the LIBRETTO–121 studies, the FDA has approved selpercatinib for adult and pediatric patients with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are...
Based on results from the LIBRETTO-001 and the LIBRETTO–121 studies, the FDA has approved selpercatinib for adult and pediatric patients with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are...
Based on results from the...
06/13/2024
Oncology
News
Selpercatinib Demonstrates Safety, Efficacy in RET-Altered NSCLC and Thyroid Cancer Regardless of Prior Treatment Status
06/28/2022
Findings from a systematic review and meta-analysis show that selpercatinib is a safe and effective option for patients with RET-altered NSCLC and thyroid cancer, regardless of previous therapies or RET alteration type.
Findings from a systematic review and meta-analysis show that selpercatinib is a safe and effective option for patients with RET-altered NSCLC and thyroid cancer, regardless of previous therapies or RET alteration type.
Findings from a systematic...
06/28/2022
Oncology
Test Your Knowledge
Quiz: Which Treatment Was Recently Granted FDA Approval for DTC?
12/06/2021
Which treatment was recently approved by the FDA for locally advanced or metastatic differentiated thyroid cancer?
Which treatment was recently approved by the FDA for locally advanced or metastatic differentiated thyroid cancer?
Which treatment was recently...
12/06/2021
Oncology
News
Air Pollution May Be Linked to Increased Occurrence of Thyroid Cancer
11/08/2021
A case-control study found that there may be a connection between air pollution exposure and an increased occurrence of thyroid cancer.
A case-control study found that there may be a connection between air pollution exposure and an increased occurrence of thyroid cancer.
A case-control study found that...
11/08/2021
Oncology
News
Pralsetinib Shows Promise in Patients with RET-Altered Thyroid Cancer
10/12/2021
Pralsetinib shows high potency and is well-tolerated in patients with RET-altered thyroid cancer, according to data from phase 1/2 of the ARROW trial.
Pralsetinib shows high potency and is well-tolerated in patients with RET-altered thyroid cancer, according to data from phase 1/2 of the ARROW trial.
Pralsetinib shows high potency...
10/12/2021
Oncology
News
FDA Approves Cabozantinib for Locally Advanced or Metastatic DTC
09/22/2021
The FDA has approved cabozantinib for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) after the results of the COSMIC-311 trial confirm significantly reduced risk...
The FDA has approved cabozantinib for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) after the results of the COSMIC-311 trial confirm significantly reduced risk...
The FDA has approved...
09/22/2021
Oncology
Test Your Knowledge
Quiz: Lenvatinib Monotherapy for Patients with Anaplastic Thyroid Cancer
09/01/2021
True or false: Results from a phase 2 trial suggest lenvatinib monotherapy may be an effective treatment for anaplastic thyroid cancer.
True or false: Results from a phase 2 trial suggest lenvatinib monotherapy may be an effective treatment for anaplastic thyroid cancer.
True or false: Results from a...
09/01/2021
Oncology
News
Lenvatinib Not Effective for Patients With Anaplastic Thyroid Cancer
08/03/2021
Lenvatinib monotherapy showed manageable safety but low activity in patients with anaplastic thyroid cancer.
Lenvatinib monotherapy showed manageable safety but low activity in patients with anaplastic thyroid cancer.
Lenvatinib monotherapy showed...
08/03/2021
Oncology
News
Cabozantinib Improves PFS in Patients with RAI-Refractory DTC
07/06/2021
Patients with RAI-refractory differentiated thyroid cancer who progressed after previous VEGFR-targeted therapy saw improved survival when treated with cabozantinib.
Patients with RAI-refractory differentiated thyroid cancer who progressed after previous VEGFR-targeted therapy saw improved survival when treated with cabozantinib.
Patients with RAI-refractory...
07/06/2021
Oncology

News

News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
FDA Approval
FDA Approves Selpercatinib for Adult and Pediatric Patients With RET Fusion-Positive Thyroid Cancer
06/13/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the LIBRETTO-001 and the LIBRETTO–121 studies, the FDA has approved selpercatinib for adult and pediatric patients with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are...
Based on results from the LIBRETTO-001 and the LIBRETTO–121 studies, the FDA has approved selpercatinib for adult and pediatric patients with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are...
Based on results from the...
06/13/2024
Oncology
News
Selpercatinib Demonstrates Safety, Efficacy in RET-Altered NSCLC and Thyroid Cancer Regardless of Prior Treatment Status
06/28/2022
Findings from a systematic review and meta-analysis show that selpercatinib is a safe and effective option for patients with RET-altered NSCLC and thyroid cancer, regardless of previous therapies or RET alteration type.
Findings from a systematic review and meta-analysis show that selpercatinib is a safe and effective option for patients with RET-altered NSCLC and thyroid cancer, regardless of previous therapies or RET alteration type.
Findings from a systematic...
06/28/2022
Oncology
News
Air Pollution May Be Linked to Increased Occurrence of Thyroid Cancer
11/08/2021
A case-control study found that there may be a connection between air pollution exposure and an increased occurrence of thyroid cancer.
A case-control study found that there may be a connection between air pollution exposure and an increased occurrence of thyroid cancer.
A case-control study found that...
11/08/2021
Oncology
News
Pralsetinib Shows Promise in Patients with RET-Altered Thyroid Cancer
10/12/2021
Pralsetinib shows high potency and is well-tolerated in patients with RET-altered thyroid cancer, according to data from phase 1/2 of the ARROW trial.
Pralsetinib shows high potency and is well-tolerated in patients with RET-altered thyroid cancer, according to data from phase 1/2 of the ARROW trial.
Pralsetinib shows high potency...
10/12/2021
Oncology
News
FDA Approves Cabozantinib for Locally Advanced or Metastatic DTC
09/22/2021
The FDA has approved cabozantinib for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) after the results of the COSMIC-311 trial confirm significantly reduced risk...
The FDA has approved cabozantinib for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) after the results of the COSMIC-311 trial confirm significantly reduced risk...
The FDA has approved...
09/22/2021
Oncology
News
Lenvatinib Not Effective for Patients With Anaplastic Thyroid Cancer
08/03/2021
Lenvatinib monotherapy showed manageable safety but low activity in patients with anaplastic thyroid cancer.
Lenvatinib monotherapy showed manageable safety but low activity in patients with anaplastic thyroid cancer.
Lenvatinib monotherapy showed...
08/03/2021
Oncology
News
Cabozantinib Improves PFS in Patients with RAI-Refractory DTC
07/06/2021
Patients with RAI-refractory differentiated thyroid cancer who progressed after previous VEGFR-targeted therapy saw improved survival when treated with cabozantinib.
Patients with RAI-refractory differentiated thyroid cancer who progressed after previous VEGFR-targeted therapy saw improved survival when treated with cabozantinib.
Patients with RAI-refractory...
07/06/2021
Oncology
News
Pesticide Exposure Linked to Increased Risk for Thyroid Cancer
05/10/2021
Results from a cohort study on male pesticide applicators found that extended use of pesticides were tied to an increased risk for thyroid cancer.
Results from a cohort study on male pesticide applicators found that extended use of pesticides were tied to an increased risk for thyroid cancer.
Results from a cohort study on...
05/10/2021
Oncology
News
Real-World Study Shows Vandetanib and Cabozantinib Effective for Advanced MTC
03/17/2021
A real-world study found both vandetanib and cabozantinib to be effective in treating patients with advanced MTC.
A real-world study found both vandetanib and cabozantinib to be effective in treating patients with advanced MTC.
A real-world study found both...
03/17/2021
Oncology

Interactive Features

Test Your Knowledge
Quiz: Which Treatment Was Recently Granted FDA Approval for DTC?
12/06/2021
Which treatment was recently approved by the FDA for locally advanced or metastatic differentiated thyroid cancer?
Which treatment was recently approved by the FDA for locally advanced or metastatic differentiated thyroid cancer?
Which treatment was recently...
12/06/2021
Oncology
Test Your Knowledge
Quiz: Lenvatinib Monotherapy for Patients with Anaplastic Thyroid Cancer
09/01/2021
True or false: Results from a phase 2 trial suggest lenvatinib monotherapy may be an effective treatment for anaplastic thyroid cancer.
True or false: Results from a phase 2 trial suggest lenvatinib monotherapy may be an effective treatment for anaplastic thyroid cancer.
True or false: Results from a...
09/01/2021
Oncology
Quiz
Quiz: Efficacy of Vandetanib, Cabozantinib for Advanced MTCctive in Treating Advanced MTC?
06/21/2021
True or False: Results from a real-world study showed that vandetanib and cabozantinib were ineffective for the treatment of patients with advanced MTC.
True or False: Results from a real-world study showed that vandetanib and cabozantinib were ineffective for the treatment of patients with advanced MTC.
True or False: Results from a...
06/21/2021
Oncology
Test Your Knowledge
Quiz: Does Artificial LAN Increase the Risk of Thyroid Cancer?
04/05/2021
True or false: Artificial LAN may increase the risk of thyroid cancer?
True or false: Artificial LAN may increase the risk of thyroid cancer?
True or false: Artificial LAN...
04/05/2021
Oncology
Test Your Knowledge
Quiz: Has Selpercatinib Been Proven Effective in Thyroid Cancer?
02/01/2021
True or false: A phase 1/2 trial found Selpercatinib to be ineffective in patients with RET-mutant medullary thyroid cancer.
True or false: A phase 1/2 trial found Selpercatinib to be ineffective in patients with RET-mutant medullary thyroid cancer.
True or false: A phase 1/2 trial...
02/01/2021
Oncology
Test Your Knowledge
Quiz: Which Treatment Was Recently Granted Accelerated Approval in RET-Altered Thyroid Cancers?
01/11/2021
Which of the following applications were recently granted accelerated approval by the FDA for adult and pediatric advanced or metastatic RET-altered thyroid cancer requiring systemic therapy?
Which of the following applications were recently granted accelerated approval by the FDA for adult and pediatric advanced or metastatic RET-altered thyroid cancer requiring systemic therapy?
Which of the following...
01/11/2021
Oncology
Test Your Knowledge
Quiz: The FDA Approved Pralsetinib For Which Type of Thyroid Cancer?
01/08/2021
The FDA recently approved pralsetinib for RET-altered _______ thyroid cancer.
The FDA recently approved pralsetinib for RET-altered _______ thyroid cancer.
The FDA recently approved...
01/08/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
FDA Approval
FDA Approves Selpercatinib for Adult and Pediatric Patients With RET Fusion-Positive Thyroid Cancer
06/13/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the LIBRETTO-001 and the LIBRETTO–121 studies, the FDA has approved selpercatinib for adult and pediatric patients with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are...
Based on results from the LIBRETTO-001 and the LIBRETTO–121 studies, the FDA has approved selpercatinib for adult and pediatric patients with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are...
Based on results from the...
06/13/2024
Oncology
News
Selpercatinib Demonstrates Safety, Efficacy in RET-Altered NSCLC and Thyroid Cancer Regardless of Prior Treatment Status
06/28/2022
Findings from a systematic review and meta-analysis show that selpercatinib is a safe and effective option for patients with RET-altered NSCLC and thyroid cancer, regardless of previous therapies or RET alteration type.
Findings from a systematic review and meta-analysis show that selpercatinib is a safe and effective option for patients with RET-altered NSCLC and thyroid cancer, regardless of previous therapies or RET alteration type.
Findings from a systematic...
06/28/2022
Oncology
News
Air Pollution May Be Linked to Increased Occurrence of Thyroid Cancer
11/08/2021
A case-control study found that there may be a connection between air pollution exposure and an increased occurrence of thyroid cancer.
A case-control study found that there may be a connection between air pollution exposure and an increased occurrence of thyroid cancer.
A case-control study found that...
11/08/2021
Oncology
News
Pralsetinib Shows Promise in Patients with RET-Altered Thyroid Cancer
10/12/2021
Pralsetinib shows high potency and is well-tolerated in patients with RET-altered thyroid cancer, according to data from phase 1/2 of the ARROW trial.
Pralsetinib shows high potency and is well-tolerated in patients with RET-altered thyroid cancer, according to data from phase 1/2 of the ARROW trial.
Pralsetinib shows high potency...
10/12/2021
Oncology
News
FDA Approves Cabozantinib for Locally Advanced or Metastatic DTC
09/22/2021
The FDA has approved cabozantinib for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) after the results of the COSMIC-311 trial confirm significantly reduced risk...
The FDA has approved cabozantinib for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) after the results of the COSMIC-311 trial confirm significantly reduced risk...
The FDA has approved...
09/22/2021
Oncology
News
Lenvatinib Not Effective for Patients With Anaplastic Thyroid Cancer
08/03/2021
Lenvatinib monotherapy showed manageable safety but low activity in patients with anaplastic thyroid cancer.
Lenvatinib monotherapy showed manageable safety but low activity in patients with anaplastic thyroid cancer.
Lenvatinib monotherapy showed...
08/03/2021
Oncology
News
Cabozantinib Improves PFS in Patients with RAI-Refractory DTC
07/06/2021
Patients with RAI-refractory differentiated thyroid cancer who progressed after previous VEGFR-targeted therapy saw improved survival when treated with cabozantinib.
Patients with RAI-refractory differentiated thyroid cancer who progressed after previous VEGFR-targeted therapy saw improved survival when treated with cabozantinib.
Patients with RAI-refractory...
07/06/2021
Oncology
News
Pesticide Exposure Linked to Increased Risk for Thyroid Cancer
05/10/2021
Results from a cohort study on male pesticide applicators found that extended use of pesticides were tied to an increased risk for thyroid cancer.
Results from a cohort study on male pesticide applicators found that extended use of pesticides were tied to an increased risk for thyroid cancer.
Results from a cohort study on...
05/10/2021
Oncology
News
Real-World Study Shows Vandetanib and Cabozantinib Effective for Advanced MTC
03/17/2021
A real-world study found both vandetanib and cabozantinib to be effective in treating patients with advanced MTC.
A real-world study found both vandetanib and cabozantinib to be effective in treating patients with advanced MTC.
A real-world study found both...
03/17/2021
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement